subject :DCGI to include Schedule HX in Drugs and Cosmetics Act:
The Union Health Ministry is leant to be reviewing the proposal of the Drug Controller General of India (DCGI) regarding the inclusion of Schedule HX in the Drugs and Cosmetics Act (D&C Act). The Schedule HX is aiming to regulate the use of antibiotics in the country.
According to the proposal of DCGI, the inclusion Schedule HX will make it mandatory for the doctors and chemists to maintain prescriptions in order to prevent the abuse of antibiotics. Around 70 drugs including antibiotics will come under the purview of new Schedule HX. Anyone caught violating the prescription would be charged a fine of Rs 20000 or up to 2 years of imprisonment.
Gulam Nabi Azad, Union Health Minster, is believed to be not in support to the proposal, considering the fact that there is huge deficit of quality doctors in the country especially in the rural areas. He has also expressed that introduction of Schedule HX would affect the health patients living in rural areas as there has been short supply of antibiotics.
subject: "Health Ministry refused introduction of rubella vaccination"
The recommendation of the National Technical Advisory Group on Immunisation (NTAGI) regarding introduction of rubella vaccination for all girls aged between 10 and 15 has been rejected by the Union Health Ministry.
According to the ministry, it is not in favour to administer rubella vaccination to the girls above 14 years in order to control the cases of Congenial Rubella Syndrome (CRS). The ministry has also made it clear that the existing system of measles, mumps and rubella (MMR) for kids under universal immunisation programme would continue with the same format. “As of now, the recommendation of the NTAGI was not considered by the ministry for implementation,” the ministry clarified.
Earlier, a public interest group alleged the government that it has not carried out any sort of study to assess the disease burden in the country. On the other hand, ministry is said to have implemented several measures for the prevention of the birth of unhealthy babies.
View Doc
subject: "Health Ministry refused introduction of rubella
vaccination"The recommendation of the National Technical Advisory Group on Immunisation (NTAGI) regarding introduction of rubella vaccination for all girls aged between 10 and 15 has been rejected by the Union Health Ministry.
According to the ministry, it is not in favour to administer rubella vaccination to the girls above 14 years in order to control the cases of Congenial Rubella Syndrome (CRS). The ministry has also made it clear that the existing system of measles, mumps and rubella (MMR) for kids under universal immunisation programme would continue with the same format. “As of now, the recommendation of the NTAGI was not considered by the ministry for implementation,” the ministry clarified.
Earlier, a public interest group alleged the government that it has not carried out any sort of study to assess the disease burden in the country. On the other hand, ministry is said to have implemented several measures for the prevention of the birth of unhealthy babies.
View Doc.
Subject: "GlaxoSmithKline puts India on radar for $2-bn acquisitions"
Global consumer healthcare company GlaxoSmithKline, has announced its expansion plans for India and is planning $2-billion acquisitions in India.
The company has considering to pump in between $500 million-$2 billion for the proposed acquisitions in India.
GSK has above $1-billion turnover from the India operations and is not willing to overpay or to engage with the large-scale merger and acquisitions.
The drug sales of GSK in emerging markets increased by 22 per cent to 3.6 billion pounds in the previous year, while it has witnessed nearly one-third increase in the profits.
The pharmaceutical market in India accounts for 5.8 billion pounds per year, which positions the country as the eighth largest pharmaceutical market globally. Moreover, the drug market is likely to register the increase of 15.7 per cent from 2010 to 2015 owing to nearly 8 per cent annual GDP growth.
The company is on high spirits with the proposal forwarded by the Industry Ministry of India to the Prime Minister seeking his consideration in the regulation of FDI into pharmaceutical companies.
According to the Health Ministry, the foreign direct investment (FDI) in pharma sector should be capped at 49 per cent amid the growing fears that acquisitions may increase the prices of generic drugs.
Subject: "MoU signed between NIPER and Russia govt to work for pharma research".
A memorandum of understanding (MoU) has been signed between the National Institute of Pharmaceutical Education and Research (NIPER) Mohali and the Russian government. Under the agreement, Volgograd State Medical University of Russia and NIPER will exchange ideas and technological research related to the pharmaceutical sciences.
“We are really very happy and excited about this tie-up as it shows the level of interest NIPER had been able to create at the international level in the field of pharma research. Through this collaboration we will be able to share information and work together to do research related activities,” said Prof. K K Bhutani, Director of NIPER Mohali.
The consultation process between both the institutions started in February 2011, following the visits of Russia delegates in India. The visiting delegates had appreciated the research activities carried out at the NIPER so they decided to join hand with the institute. Commenting over the MoU, Prof Bhutani has also said that the agreement is in accordance of vision 2020 that pledges to develop innovative Russian pharmaceuticals for the India pharma industry.
Subject: Pharmexcil Patents National Award 2010-11 won
www.parasshah.weebly.com2:06am Oct
10Pharmexcil Patents National Award 2010-11 won by Green Chem:
The herbal extracts manufacturing company Green Chem has won Pharmexcil Patents National Award 2010-11. The company has bagged this award for the third consecutive year since 2008-09.
Recently, Kiran Kumar Reddy, Chief Minister of Andhra Pradesh, conferred the award at an India–Latin American Country (LAC) Pharma Business Meet in the city. The company exports its entire herbal extracts for nutraceuticals and it also runs organic farms for the cultivation of several important herbs.
There are more than 150 herbs being offered by the company. These products are related to slimming, joint pain relieving, male and female libido increasing, improvement blood circulation, skin care, wound healing, natural minerals supplement, memory power improving, natural vitamins supplement and antioxidant. At present, these products are being exported to the countries like Germany, Austria, USA, Australia, Korea, South Africa, Canada, Brazil, Mexico, New Zealand, Norway, China and many others.
Subject: [pharmacyforum] News: Experimental Oral MS Treatment Fails To Meet Efficacy Goal In Clinical Trial.
The AP (8/1) reported, Teva Pharmaceutical Industries Ltd. "said its experimental drug laquinimod, an oral treatment for multiple sclerosis, did not reduce patients' annual relapse rate in a late-stage clinical trial."
Bloomberg News (8/2, Kresge) reports, Laquinimod reduced "relapses by 17.6 percent versus placebo," but the result "wasn't statistically significant," Teva executives told analysts on a conference call Monday.. After accounting for the MRI differences, laquinimod "showed a statistically significant 21 percent reduction in relapses" but Biogen's Avonex (interferon beta-1a) cut relapses by "29 percent after the adjustment and by 26 percent prior to it," the Petach Tikva, Israel-based company officials said.
The Wall Street Journal (8/2, Gryta, Subscription Publication) reports that because the adjusted data analysis indicated laquinimod was successful along several efficacy measurements, Teva and Active Biotech said they will still submit the treatment for regulatory approval in the US and European Union early next year. Medscape (8/1, Jeffrey) noted that Teva and Active Biotech issued a statement Monday outlining the results.
Subject: [pharmacyforum] News: FDA Approves Subcutaneous Formulation Of Abatacept To Treat RA.
MedPage Today (8/2, Gever) reported that to Bristol-Myers Squibb announced that the FDA has approved a formulation of its "rheumatoid arthritis drug abatacept (Orencia) that patients can self-inject subcutaneously." Previously, abatacept was available only as an "intravenous infusion." With the newly approved indication, BMS said patients will be able to "administer the biologic drug themselves at home." The subcutaneous formulation is to be "given as a 125-mg fixed dose weekly, preferably after an initial intravenous loading dose of 10 mg/kg."
Medscape (8/2, Hitt) added that patients who are unable to receive an infusion may initiate weekly injections of subcutaneous abatacept without an intravenous loading dose, according to BMS' announcement. In a large clinical trial, subcutaneous abatacept was "noninferior compared with intravenous dosing in terms of responses to American College of Rheumatology (ACR) 20 criteria at six months and safety." However, abatacept "should not be used concurrently with TNF antagonists," the study concluded.
Subject: CANADA - Spot Admissions- Ahmedabad
Dear Students,
Greetings !!!
We herewith bring you one more golden opportunity to attend the Spot Admissions of Algonquin College one of the best Canadian SPP College? in Ahmedabad
Highlights ?
1. Meet the Direct representatives of the College and discuss your queries on the spot
2. Eligible candidates will get the offer letters immediately.
3. Best chance to reserve your seat for one of the leading Canadian college.
4. Save the Application fees.
Registration ?
1. Prior Registration is Compulsory for attending the spot admission event.
2. Bring along your Original + 3 Copies of All your academic Documents .
For Registration No.
Call on ? 9879066300 OR ;
SMS your Name and Mail ID on ? 9879066300
Date & Venue ?
Date ? 11st Oct.2011. Tuesday
Time ? 3 PM to 5 PM
Venue ? 302, City Square, University Road, Ahmedabad 380015
So Hurry Up , Don?t Miss this Golden Opportunity to Choose an INTERNATIONAL CAREER.
With Best Regards
www.parasshah.weebly.com